ArticleAmerican journal of translational research2025
YiQiWenShen formula ameliorates myasthenia gravis through T follicular helper cells/T follicular regulatory cells immune rebalancing.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyasthenia gravis (MG), a chronic autoimmune neuromuscular disorder characterized by muscle weakness, remains a therapeutic challenge. This study aimed to evaluate the efficacy of the traditional Chinese herbal formulation YiQiWenShen (YQWS) in comparison with prednisone in a rat model of experimental autoimmune myasthenia gravis (EAMG), with the goal of exploring new therapeutic strategies.
methodsEAMG was induced in rats, who were subsequently treated with different doses of YQWS and prednisone. Clinical severity was assessed using the Baggi scoring system, alongside measurements of body weight, serum acetylcholine receptor antibody (AChR-Ab) levels, and splenic lymphocyte proliferation in response to the rat AChRα97-116 peptide and concanavalin A. Cytokine profiles, proportions of T follicular helper (Tfh) cells, T follicular regulatory (Tfr) cells, and germinal center B (GC)-B cells in lymph nodes were analyzed using enzyme-linked immunosorbent assay and flow cytometry. The expression levels of B-cell lymphoma 6 (Bcl-6) mRNA and protein were analyzed using quantitative real-time polymerase chain reaction and western blot, respectively.
resultsAfter EAMG induction, the rats exhibited significant weight loss, elevated clinical scores, and increased AChR-Ab levels. Both YQWS and prednisone treatments significantly improved body weight and clinical scores, and reduced serum AChR-Ab levels. YQWS also attenuated the increased splenic lymphocyte proliferation. Cytokine dysregulation observed in EAMG rats was partially corrected following YQWS treatment. Furthermore, both YQWS and prednisone effectively normalized the Tfh/Tfr cell ratio, decreased GC-B cell populations, and downregulated Bcl-6 expression.
conclusionYQWS exerts therapeutic effects in EAMG comparable to those of prednisone, demonstrating its potential as an alternative treatment for MG. Its efficacy is associated with the normalization of body weight, modulation of immune responses, correction of cytokine imbalances and reestablishment of Tfh/Tfr and GC-B cell homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.